Life Sciences + Health

Communication Solutions into 250+ Languages for a Healthier World

Ensuring Quality In A Strategic Medical Writing Partnership

While quality is subjective and holds many different definitions depending on that in question, when in a strategic partnership it must be measured, monitored, and regulated to ensure a successful and open relationship from vendor to client. Read more in our new white paper how to ensure quality in strategic medical writing partnerships.

Translating Lay Summaries – Driving Transparency

For clinical trials, the importance of transparent communication and understanding is critical in building trust with patients. Lay summaries, which break down complex study results in an easy, digestible way, are a great way to ensure patient participants understand both treatment and clinical trial results. Learn about the need for accurate translation of lay summaries for driving transparency for patients involved in global clinical trials in our latest blog post!

Medical Writing

Medical writing expertise in 250+ languages, from regulatory, publication, and safety writing services to medico-marketing solutions

Resurgence of COVID-19 Cases in European Cities Causes New Restrictions

In the most recent report from the UK this past week, cases of COVID-19 have doubled to about 6,000 per day.

We are dedicated to industry-standard knowledge and quality

Helping You Globalize the Right Way

CSOFT’s experienced and dedicated global regulatory submission specialists help companies comply with these demanding multilingual documentation requirements for submissions while providing the highest linguistic quality

We can help you attain the appropriate, accurate, and sustainable compliance required throughout the entire submission process. We ensure our clients receive the necessary certifications to successfully enter emerging markets.

Medical Translation with a Focus on Precision

Our translation solutions are intended for document types relating to every stage of product development life cycle.

Quality in translation is extremely important, but within the life sciences industry, incorrect translations could literally be life threatening. We use industry-standard processes, however, we also offer flexibility for each customer to allow for their companies’ success, no matter the process.


Industries We Serve

Who We Are

CSOFT Health Sciences provides end-to-end medical translations for all phases of the product lifecycle, from pre-clinical to post-launch. We also specialize in market access consulting, medical writing, and CTD/eCTD submissions with the FDA, EMA, and NMPA.

Our operations are compliant with ISO 17100 and certified in ISO 9001:2015 and ISO 13485:2016, ensuring our customized solutions meet the rigorous regulatory requirements of global submissions.

The Power of Linguistic Expertise

Right Tools. Right Resources

Tools we use

CAT Tools: Trados, MemoQ, Transifex, Smartling, WordServer

We translate all document types (.ai, .doc, .pdf, .ppt, .xlx, .css, .php, .html, .xml, .mml, .txt, .mpg, .mov, .zip, .psd, and more)

Linguists we hire

Our native in-country subject-matter experts with at least 7 years’ experience go through a rigorous certification process and are guided with customer experience surveys

Methodologies we employ

Customized solutions
Translation Memory
Style Guides & Glossary

CSOFT works extensively with medical professionals who are dedicated to prevalent therapeutic areas

Start Your Global Journey


501 Boylston Street, 10th Floor
Boston, MA 02116


The Knowledge Vault

Stay in the know

CSOFT life science blog aims to provide a better understanding of complex diseases, and regulatory policies from conducting experiments to introducing new type of drugs into the market. 

FDA Approves Edwards’ Sapien 3 for Cardiac Treatment

Edwards Lifesciences has developed the Sapien 3 transcatheter heart valve which was approved yesterday (9/8) by the U.S. Food and Drug Administration (FDA) for pediatric and adult patients. Transcatheter heart valves is an option for the new patient population...